冬病夏治哮喘膏联合孟鲁司特防治儿童支气管哮喘的疗效观察

Observation on curative effect of montelukast combined with winter disease cured in summer asthma ointment on chronic bronchial asthma

关键词:  支气管哮喘  孟鲁斯特  冬病夏治  哮喘贴

Key words:  bronchial asthma  montelukast  winter disease cured in summer  asthma plaster

摘要:

[目的]评价冬病夏治哮喘膏联合孟鲁司特防治儿童支气管哮喘的疗效及安全性。[方法]110例儿童支气管哮喘患者随机均分为研究组与对照组，两组患者均采用常规治疗，在此基础上，对照组采用孟鲁司特钠片治疗3个月，研究组在对照组基础上加用冬病夏治哮喘膏，一伏、二伏、三伏每次贴敷均2~3 h，每年三伏结束为1个疗程，均接受1个疗程治疗，且随访1 a。比较两组治疗效果，采用肺功能仪测定两组用力肺活量（FVC）、第1秒用力呼吸容积（FEV1）的变化；采用酶联免疫吸附法测定治疗前后两组核因子κB（NF-κB）、白介素-6（IL-6）、白介素-8（IL-8）水平的变化；记录治疗前后哮喘症状积分；并监测两组治疗的安全性，统计复发率。[结果]1）研究组患者总有效率为96.36%，高于对照组的80.00%，差异有统计学意义（P<0.05）。2）治疗后，两组患者治疗6个月及8个月后FVC、FEV1均高于治疗前，且治疗12个月高于治疗6个月后，研究组高于对照组，差异均有统计学意义（P<0.05）。3）治疗后，两组患者治疗6个月及8个月后NF-κB、IL-6、IL-8均低于治疗前，治疗12个月后低于治疗6个月后，研究组各指标下降幅度均高于对照组，差异均有统计学意义（P<0.05）。4）研究组随访期间复发1例（1.82%），对照组复发9例（16.36%），两组复发率对比差异有统计学意义（P<0.05）。[结论]采用冬病夏治哮喘膏联合孟鲁司特防治儿童支气管哮喘，可改善患者肺功能，降低炎性因子水平，降低哮喘复发率，且安全性较高。

Abstract:

[Objective] To evaluate the curative effect and safety of montelukast combined with winter disease cured in summer asthma ointment in the treatment of chronic bronchial asthma.[Methods] The 110 cases of patients with chronic bronchial asthma were randomly divided into the study group and the control group. Both of the two groups were treated with routine treatment. Based on this, the control group was treated with montelukast sodium tablets. The study group was additionally treated with winter disease cured in summer asthma ointment (Dog Day-Sanku plaster) based on the treatment in the control group, differentiation of syndromes to get the point, in the first, second and third dog day, the plasters were attached 2~3 h/time. The end of dog day each year was taken as 1 course of treatment. All of them received 1courses of treatment and were followed up for 1 year. The curative effect was compared between the two groups. The changes of forced vital capacity (FVC) and forced respiratory volume in 1 second (FEV1) in the two groups were measured by the pulmonary function instrument; changes of nuclear factor kappa B signaling pathway (NF-κB), interleukin-6 (IL-6) and interleukin-8 (IL-8) levels in the two group before and after treatment were measured by enzyme linked immunosorbent assay (ELISA); the improvement of asthma symptom score was recorded before and after treatment. Safety of treatment in the two groups was monitored and the recurrence rate was statistically analyzed.[Results] 1) The total effective rate in the study group (96.36%) was higher than that in the control group (80.00%, P<0.05); 2) Six months and 8 months after treatment, FVC and FEV1 in the two groups were higher than those before treatment. Those 12 months after treatment was higher than those 6 months after treatment and those in the study group were higher than those in the control group (P<0.05); 3) Six months and 8 months after treatment, NF-κB, IL-6 and IL-8 in the two groups were lower than those before treatment and those 12 months after treatment were lower than those 6 months after treatment. The decreasing range of indexes in the study group was greater than that in the control group (P<0.05); 4) There was recurrence in1 case (1.82%) in the control group and 9 cases (16.36%) in the control group during follow-up period (P<0.05).[Conclusions] To adopt montelukast combined with winter disease cured in summer asthma ointment in the treatment of chronic bronchial asthma can improve the lung function, reduce the levels of inflammatory factors and reduce the recurrence rate of asthma and it has high safety.